title: Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment.
abstract: BACKGROUND
  Quality of life is an area of increasing interest in hepatology. Studies, so far, have assessed quality of life in patients with chronic virus C-related hepatitis in relation to antiviral therapy by means of generic questionnaires.
  
  
  OBJECTIVE
  To measure quality of life in chronic hepatitis patients without cirrhosis by means of the Nottingham Health Profile questionnaire, a measure of "distress" in comparison with the Medical Outcome Survey SF-36, an index of well-being.
  
  
  METHODS
  A series of 126 outpatients with chronic hepatitis; 37 on and 89 not on active interferon treatment.
  
  
  METHODS
  The two questionnaires were used in random order. Clinical and laboratory data were also collected. The final score of any domain of the two questionnaires, for any individual patient, was compared to age-adjusted normal values obtained in 2 random samples of Italian population.
  
  
  RESULTS
  Patients showed a significant modification of 3 domains of Nottingham Health Profile (Energy, Social Isolation and Physical Mobility) and 6 domains of SF-36. In relation to interferon treatment, the Nottingham Health Profile questionnaire was able to detect differences in Energy, Physical Mobility and Pain, which were modified only in treated patients. SF-36 did not show any differences in relation to treatment. In addition, the Nottingham Health Profile demonstrated that treated patients had a lower prevalence of concern for family life, possibly due to expectations of treatment itself.
  
  
  CONCLUSIONS
  Active interferon treatment causes considerable distress in chronic hepatitis C patients, adding to the perceived change in health status caused by liver disease.
authors.affiliation: Department of Internal Medicine, University of Bologna, Italy. bianmice@almadns.unibo.it
authors.forename: G
authors.initials: G
authors.lastname: Bianchi
authors.forename: C
authors.initials: C
authors.lastname: Loguercio
authors.forename: D
authors.initials: D
authors.lastname: Sgarbi
authors.forename: R
authors.initials: R
authors.lastname: Abbiati
authors.forename: C H
authors.initials: CH
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Di Pierro
authors.forename: D
authors.initials: D
authors.lastname: Disalvo
authors.forename: S
authors.initials: S
authors.lastname: Natale
authors.forename: G
authors.initials: G
authors.lastname: Marchesini
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D019698:Hepatitis C, Chronic / Q000523:psychology* / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D007372:Interferons